Bioverativ Therapeutics Inc. drugs

3 results

  • alprolix

    (Coagulation Factor IX (Recombinant), Fc Fusion Protein)
    Bioverativ Therapeutics Inc.
    ALPROLIX is indicated for the on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis in adults and children with hemophilia B. It is not intended for inducing immune tolerance.

  • altuviiio

    (Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl)
    Bioverativ Therapeutics Inc.
    ALTUVIIIO is indicated for adults and children with hemophilia A for routine prophylaxis to reduce bleeding episodes, on-demand treatment, and perioperative bleeding management. It is not intended for treating von Willebrand disease.

  • eloctate

    (Antihemophilic Factor (Recombinant), Fc Fusion Protein)
    Bioverativ Therapeutics Inc.
    ELOCTATE is indicated for the treatment and control of bleeding episodes, perioperative management, and routine prophylaxis in adults and children with Hemophilia A. It is not indicated for von Willebrand disease.